AU5871694A - Combination for treating hiv infections containing thymosine, interleukin and hiv replication or reverse transcriptase inhibitors - Google Patents
Combination for treating hiv infections containing thymosine, interleukin and hiv replication or reverse transcriptase inhibitorsInfo
- Publication number
- AU5871694A AU5871694A AU58716/94A AU5871694A AU5871694A AU 5871694 A AU5871694 A AU 5871694A AU 58716/94 A AU58716/94 A AU 58716/94A AU 5871694 A AU5871694 A AU 5871694A AU 5871694 A AU5871694 A AU 5871694A
- Authority
- AU
- Australia
- Prior art keywords
- thymosine
- interleukin
- combination
- reverse transcriptase
- transcriptase inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 102000015696 Interleukins Human genes 0.000 title 1
- 108010063738 Interleukins Proteins 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99088792A | 1992-12-15 | 1992-12-15 | |
PCT/US1993/012171 WO1994013314A1 (en) | 1992-12-15 | 1993-12-15 | Combination for treating hiv infections containing thymosine, interleukin and hiv replication or reverse transcriptase inhibitors |
US990887 | 1997-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5871694A true AU5871694A (en) | 1994-07-04 |
Family
ID=25536618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU58716/94A Abandoned AU5871694A (en) | 1992-12-15 | 1993-12-15 | Combination for treating hiv infections containing thymosine, interleukin and hiv replication or reverse transcriptase inhibitors |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPH07267874A (en) |
CN (1) | CN1094310A (en) |
AU (1) | AU5871694A (en) |
WO (1) | WO1994013314A1 (en) |
ZA (1) | ZA939217B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
DE19608280A1 (en) * | 1996-02-23 | 1997-08-28 | Strathmann Ag & Co | Causal treatment of infection by human or simian immunodeficiency virus |
AU6761198A (en) * | 1998-03-17 | 1999-10-11 | Julianna Lisziwiewicz | Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor |
US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
CA2464228C (en) | 2000-10-27 | 2017-01-17 | Immuno-Rx, Inc. | Vaccine immunotherapy for immune suppressed patients |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
UA78726C2 (en) | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
CN100501400C (en) | 2002-11-25 | 2009-06-17 | 希克龙制药公司 | Methods of protecting against radiation damage using alpha thymosin |
WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
JP2012526149A (en) | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | Alpha thymosin peptide as a vaccine enhancer |
JP5797190B2 (en) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス, インコーポレイテッド | Vaccine immunotherapy |
AU2010328197B2 (en) | 2009-12-08 | 2015-07-16 | Irx Therapeutics, Inc. | Method of reversing immune suppression of Langerhans cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1238231B (en) * | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | USE OF IMMUNOMODULANTS AS SYNERGIC AGENTS OF CHEMOTHERAPY IN CANCER THERAPY |
-
1993
- 1993-09-27 CN CN93119207A patent/CN1094310A/en active Pending
- 1993-12-08 ZA ZA939217A patent/ZA939217B/en unknown
- 1993-12-15 AU AU58716/94A patent/AU5871694A/en not_active Abandoned
- 1993-12-15 JP JP5314746A patent/JPH07267874A/en not_active Withdrawn
- 1993-12-15 WO PCT/US1993/012171 patent/WO1994013314A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1994013314A1 (en) | 1994-06-23 |
JPH07267874A (en) | 1995-10-17 |
CN1094310A (en) | 1994-11-02 |
ZA939217B (en) | 1994-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2216292A (en) | Inhibitors of hiv reverse transcriptase | |
AU4205789A (en) | Method and composition for the treatment and prevention of viral infections | |
AU6276194A (en) | Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer | |
CA2105487A1 (en) | Antiviral nucleoside combination | |
AU6077394A (en) | Operating tables, trolleys and transfer systems | |
EP0462800A3 (en) | Inhibitors of hiv reverse transcriptase | |
HU9502468D0 (en) | Inhibitors of hiv reverse transcriptase | |
AU1694295A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
AU4691789A (en) | N-aryl-azetidinones, their preparation process and their use as elastase inhibitors | |
EP0604182A3 (en) | Inhibitors of HIV protease useful for the treatment of Aids. | |
EP0643580A4 (en) | Combinations of ace inhibitors and diuretics. | |
AU8693491A (en) | Synergism of hiv reverse transcriptase inhibitors | |
AU3780393A (en) | Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents | |
AU5871694A (en) | Combination for treating hiv infections containing thymosine, interleukin and hiv replication or reverse transcriptase inhibitors | |
AU5254696A (en) | Reduced toxicity compositions and methods for treating hiv infections | |
CA2168447A1 (en) | Compounds and methods for inhibition of hiv and related viruses | |
PL312908A1 (en) | Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors | |
EP0643074A3 (en) | Viral infection and proliferation inhibitors. | |
EP0656069A4 (en) | Inhibitors of cell proliferation, their preparation and use. | |
AR244941A1 (en) | Compound, composition, procedure and use of an anti microbial product. | |
AU7732691A (en) | Hiv protease inhibitors and processes for their preparation | |
AU7845191A (en) | Inhibitors of HIV reverse transcriptase | |
PL308551A1 (en) | Application of bhpa compounds in combination with other nucleosidal inhibitors of reverse transcriptase in treating hiv infections | |
AU4698399A (en) | 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors | |
EP0624567A3 (en) | Derivatives of 3-fluorophenol, process for their preparation and their use. |